Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Bañez LL[au]:

Comparison of rituximab and conventional adjuvant therapy for pemphigus vulgaris: A retrospective analysis. Agarwal A et al. PLoS One. (2018)

VEGF inhibitors in cancer therapy. Cardones AR et al. Curr Pharm Des. (2006)

Commentary on EPC methods: an exploration of the use of text-mining software in systematic reviews. Paynter R et al. J Clin Epidemiol. (2017)

Search results

Items: 1 to 50 of 70

1.

Interrater Reliability of Clinical Grading Measures for Cutaneous Chronic Graft-vs-Host Disease.

Cardones AR, Sullivan KM, Green C, Chao NJ, Rowe-Nichols K, Bañez LL, Burton CS, Horwitz ME, Long GD, Rao CL, Sarantopoulos S, Sidhu-Malik N, Sung AD, Hall RP 3rd.

JAMA Dermatol. 2019 Jul 1;155(7):833-837. doi: 10.1001/jamadermatol.2018.5459.

PMID:
30994873
2.

Comparison of rituximab and conventional adjuvant therapy for pemphigus vulgaris: A retrospective analysis.

Agarwal A, Hall RP 3rd, Bañez LL, Cardones AR.

PLoS One. 2018 Sep 25;13(9):e0198074. doi: 10.1371/journal.pone.0198074. eCollection 2018.

3.

Prioritization and Selection of Harms for Inclusion in Systematic Reviews.

Chou R, Baker WL, Bañez LL, Iyer S, Myers ER, Newberry S, Pincock L, Robinson KA, Sardenga L, Sathe N, Springs S, Wilt TJ.

Methods Guide for Effectiveness and Comparative Effectiveness Reviews [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2008-.
2018 Feb 2.

4.

Agency for Healthcare Research and Quality Evidence-based Practice Center methods provide guidance on prioritization and selection of harms in systematic reviews.

Chou R, Baker WL, Bañez LL, Iyer S, Myers ER, Newberry S, Pincock L, Robinson KA, Sardenga L, Sathe N, Springs S, Wilt TJ.

J Clin Epidemiol. 2018 Jun;98:98-104. doi: 10.1016/j.jclinepi.2018.01.007. Epub 2018 Feb 2. Review.

PMID:
29409913
5.

Commentary on EPC methods: an exploration of the use of text-mining software in systematic reviews.

Paynter R, Bañez LL, Erinoff E, Lege-Matsuura J, Potter S.

J Clin Epidemiol. 2017 Apr;84:33-36. doi: 10.1016/j.jclinepi.2016.11.019. Epub 2017 Jan 18. No abstract available.

PMID:
28108352
6.

EPC Methods: An Exploration of the Use of Text-Mining Software in Systematic Reviews [Internet].

Paynter R, Bañez LL, Berliner E, Erinoff E, Lege-Matsuura J, Potter S, Uhl S.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2016 Apr.

7.

Does the multidisciplinary approach improve oncological outcomes in men undergoing surgical treatment for prostate cancer?

Stewart SB, Moul JW, Polascik TJ, Koontz BF, Robertson CN, Freedland SJ, George DJ, Lee WR, Armstrong AJ, Bañez LL.

Int J Urol. 2014 Dec;21(12):1215-9. doi: 10.1111/iju.12561. Epub 2014 Jul 14.

8.

High serum folate is associated with reduced biochemical recurrence after radical prostatectomy: results from the SEARCH Database.

Moreira DM, Bañez LL, Presti JC Jr, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ.

Int Braz J Urol. 2013 May-Jun;39(3):312-8; discussion 319. doi: 10.1590/S1677-5538.IBJU.2013.03.03.

9.

Emergent ureteric stent vs percutaneous nephrostomy for obstructive urolithiasis with sepsis: patterns of use and outcomes from a 15-year experience.

Goldsmith ZG, Oredein-McCoy O, Gerber L, Bañez LL, Sopko DR, Miller MJ, Preminger GM, Lipkin ME.

BJU Int. 2013 Jul;112(2):E122-8. doi: 10.1111/bju.12161.

10.

Reply to association between exercise and primary incidence of prostate cancer: does race matter?

Bañez LL, Singh AA.

Cancer. 2013 Sep 1;119(17):3251-2. doi: 10.1002/cncr.28178. Epub 2013 Jun 3. No abstract available.

11.

Statin use and risk of prostate cancer and high-grade prostate cancer: results from the REDUCE study.

Freedland SJ, Hamilton RJ, Gerber L, Banez LL, Moreira DM, Andriole GL, Rittmaster RS.

Prostate Cancer Prostatic Dis. 2013 Sep;16(3):254-9. doi: 10.1038/pcan.2013.10. Epub 2013 Apr 9.

PMID:
23567655
12.

Intratumoral inflammation is associated with more aggressive prostate cancer.

Klink JC, Bañez LL, Gerber L, Lark A, Vollmer RT, Freedland SJ.

World J Urol. 2013 Dec;31(6):1497-503. doi: 10.1007/s00345-013-1065-8. Epub 2013 Apr 2.

PMID:
23546767
13.

Androgenetic alopecia at various ages and prostate cancer risk in an equal-access multiethnic case-control series of veterans.

Thomas JA, Antonelli JA, Banez LL, Hoyo C, Grant D, Demark-Wahnefried W, Platz EA, Gerber L, Shuler K, Eyoh E, Calloway E, Freedland SJ.

Cancer Causes Control. 2013 May;24(5):1045-52. doi: 10.1007/s10552-013-0182-4. Epub 2013 Mar 26.

14.

Sexual bother and function after radical prostatectomy: predictors of sexual bother recovery in men despite persistent post-operative sexual dysfunction.

Kimura M, Bañez LL, Polascik TJ, Bernal RM, Gerber L, Robertson CN, Donatucci CF, Moul JW.

Andrology. 2013 Mar;1(2):256-61. doi: 10.1111/j.2047-2927.2012.00036.x. Epub 2012 Nov 29.

15.

Association between exercise and primary incidence of prostate cancer: does race matter?

Singh AA, Jones LW, Antonelli JA, Gerber L, Calloway EE, Shuler KH, Freedland SJ, Grant DJ, Hoyo C, Bañez LL.

Cancer. 2013 Apr 1;119(7):1338-43. doi: 10.1002/cncr.27791. Epub 2013 Feb 11.

16.

Development and clinical validation of a real-time PCR assay for PITX2 DNA methylation to predict prostate-specific antigen recurrence in prostate cancer patients following radical prostatectomy.

Dietrich D, Hasinger O, Bañez LL, Sun L, van Leenders GJ, Wheeler TM, Bangma CH, Wernert N, Perner S, Freedland SJ, Corman JM, Ittmann MM, Lark AL, Madden JF, Hartmann A, Schatz P, Kristiansen G.

J Mol Diagn. 2013 Mar;15(2):270-9. doi: 10.1016/j.jmoldx.2012.11.002. Epub 2012 Dec 22.

17.

Race is associated with discontinuation of active surveillance of low-risk prostate cancer: results from the Duke Prostate Center.

Abern MR, Bassett MR, Tsivian M, Bañez LL, Polascik TJ, Ferrandino MN, Robertson CN, Freedland SJ, Moul JW.

Prostate Cancer Prostatic Dis. 2013 Mar;16(1):85-90. doi: 10.1038/pcan.2012.38. Epub 2012 Oct 16.

PMID:
23069729
18.

African-American men with low-grade prostate cancer have higher tumor burdens: results from the Duke Prostate Center.

Tsivian M, Bañez LL, Keto CJ, Abern MR, Qi P, Gerber L, Moul JW, Polascik TJ.

Prostate Cancer Prostatic Dis. 2013 Mar;16(1):91-4. doi: 10.1038/pcan.2012.39. Epub 2012 Oct 2.

PMID:
23032361
19.

Preoperative predictors of pathologic stage T2a in low-risk prostate cancer: implications for focal therapy.

Fu Q, Moul JW, Bañez LL, Sun L, Mouraviev V, Xie D, Polascik TJ.

Urol Int. 2012;89(3):296-300. doi: 10.1159/000341556. Epub 2012 Sep 6.

PMID:
22964539
20.

The impact of obesity on the predictive accuracy of PSA in men undergoing prostate biopsy.

Bañez LL, Albisinni S, Freedland SJ, Tubaro A, De Nunzio C.

World J Urol. 2014 Apr;32(2):323-8. doi: 10.1007/s00345-012-0919-9. Epub 2012 Jul 31.

PMID:
22847453
21.

Outcomes of metallic stents for malignant ureteral obstruction.

Goldsmith ZG, Wang AJ, Bañez LL, Lipkin ME, Ferrandino MN, Preminger GM, Inman BA.

J Urol. 2012 Sep;188(3):851-5. doi: 10.1016/j.juro.2012.04.113. Epub 2012 Jul 20.

PMID:
22819410
22.

Long-term oncological outcomes of men undergoing radical prostatectomy with preoperative prostate-specific antigen <2.5 ng/ml and 2.5-4 ng/ml.

Qi P, Tsivian M, Abern MR, Bañez LL, Tang P, Moul JW, Polascik TJ.

Urol Oncol. 2013 Nov;31(8):1527-32. doi: 10.1016/j.urolonc.2012.06.003. Epub 2012 Jul 12.

PMID:
22795501
23.

Association between percentage of tumor involvement and Gleason score upgrading in low-risk prostate cancer.

Fu Q, Moul JW, Bañez LL, Sun L, Mouraviev V, Xie D, Polascik TJ.

Med Oncol. 2012 Dec;29(5):3339-44. doi: 10.1007/s12032-012-0270-4. Epub 2012 Jun 12.

PMID:
22688447
24.

Greater percent-free testosterone is associated with high-grade prostate cancer in men undergoing prostate biopsy.

Albisinni S, De Nunzio C, Tubaro A, Barry WT, Banez LL, Freedland SJ.

Urology. 2012 Jul;80(1):162-7. doi: 10.1016/j.urology.2012.01.068. Epub 2012 May 18.

PMID:
22608797
25.

Predicting participation in and successful outcome of a penile rehabilitation programme using a phosphodiesterase type 5 inhibitor with a vacuum erection device after radical prostatectomy.

Kimura M, Caso JR, Bañez LL, Koontz BF, Gerber L, Senocak C, Donatucci CF, Vujaskovic Z, Moul JW, Polascik TJ.

BJU Int. 2012 Dec;110(11 Pt C):E931-8. doi: 10.1111/j.1464-410X.2012.11168.x. Epub 2012 Apr 23.

26.

Association of prostate-specific antigen doubling time and cancer in men undergoing repeat prostate biopsy.

Moreira DM, Gerber L, Thomas JA, Bañez LL, McKeever MG, Freedland SJ.

Int J Urol. 2012 Aug;19(8):741-7. doi: 10.1111/j.1442-2042.2012.03016.x. Epub 2012 Apr 4.

27.

Editorial comment.

Singh AA, Bañez LL.

J Urol. 2012 May;187(5):1593. doi: 10.1016/j.juro.2011.12.156. Epub 2012 Mar 14. No abstract available.

PMID:
22425111
28.

Prostate cancer risk in men with baseline history of coronary artery disease: results from the REDUCE Study.

Thomas JA 2nd, Gerber L, Bañez LL, Moreira DM, Rittmaster RS, Andriole GL, Freedland SJ.

Cancer Epidemiol Biomarkers Prev. 2012 Apr;21(4):576-81. doi: 10.1158/1055-9965.EPI-11-1017. Epub 2012 Feb 7.

29.

Pretreatment expectations of patients undergoing robotic assisted laparoscopic or open retropubic radical prostatectomy.

Schroeck FR, Krupski TL, Stewart SB, Bañez LL, Gerber L, Albala DM, Moul JW.

J Urol. 2012 Mar;187(3):894-8. doi: 10.1016/j.juro.2011.10.135. Epub 2012 Jan 15.

PMID:
22245326
30.

Prostate cancer risk in men with prostate and breast cancer family history: results from the REDUCE study (R1).

Thomas JA 2nd, Gerber L, Moreira DM, Hamilton RJ, Bañez LL, Castro-Santamaria R, Andriole GL, Isaacs WB, Xu J, Freedland SJ.

J Intern Med. 2012 Jul;272(1):85-92. doi: 10.1111/j.1365-2796.2011.02504.x. Epub 2012 Jan 16.

31.

Association between preoperative erectile dysfunction and prostate cancer features--an analysis from the Duke Prostate Center Database.

Kimura M, Bañez LL, Gerber L, Qi J, Tsivian M, Freedland SJ, Satoh T, Polascik TJ, Baba S, Moul JW.

J Sex Med. 2012 Apr;9(4):1174-81. doi: 10.1111/j.1743-6109.2011.02547.x. Epub 2011 Dec 21.

PMID:
22188861
32.

Utilization trends at a multidisciplinary prostate cancer clinic: initial 5-year experience from the Duke Prostate Center.

Stewart SB, Bañez LL, Robertson CN, Freedland SJ, Polascik TJ, Xie D, Koontz BF, Vujaskovic Z, Lee WR, Armstrong AJ, Febbo PG, George DJ, Moul JW.

J Urol. 2012 Jan;187(1):103-8. doi: 10.1016/j.juro.2011.09.040. Epub 2011 Nov 16.

PMID:
22088334
33.

Editorial comment.

Ho TS, Bañez LL, Freedland SJ.

Urology. 2011 Oct;78(4):872-3. doi: 10.1016/j.urology.2011.06.025. No abstract available.

PMID:
21982005
34.

Factors predicting early and late phase decline of sexual health-related quality of life following radical prostatectomy.

Kimura M, Bañez LL, Schroeck FR, Gerber L, Qi J, Satoh T, Baba S, Robertson CN, Walther PJ, Donatucci CF, Moul JW, Polascik TJ.

J Sex Med. 2011 Oct;8(10):2935-43. doi: 10.1111/j.1743-6109.2011.02387.x. Epub 2011 Jul 19.

PMID:
21771284
35.

Predictive value of digital rectal examination for prostate cancer detection is modified by obesity.

Chu DI, De Nunzio C, Gerber L, Thomas JA 2nd, Calloway EE, Albisinni S, Senocak C, McKeever MG, Moreira DM, Tubaro A, Moul JW, Freedland SJ, Bañez LL.

Prostate Cancer Prostatic Dis. 2011 Dec;14(4):346-53. doi: 10.1038/pcan.2011.31. Epub 2011 Jul 5.

36.

Risk of death from prostate cancer after radical prostatectomy or brachytherapy in men with low or intermediate risk disease.

Arvold ND, Chen MH, Moul JW, Moran BJ, Dosoretz DE, Bañez LL, Katin MJ, Braccioforte MH, D'Amico AV.

J Urol. 2011 Jul;186(1):91-6. doi: 10.1016/j.juro.2011.03.003. Epub 2011 May 14.

PMID:
21571341
37.

The association of diabetes mellitus and high-grade prostate cancer in a multiethnic biopsy series.

Moreira DM, Anderson T, Gerber L, Thomas JA, Bañez LL, McKeever MG, Hoyo C, Grant D, Jayachandran J, Freedland SJ.

Cancer Causes Control. 2011 Jul;22(7):977-83. doi: 10.1007/s10552-011-9770-3. Epub 2011 May 12.

PMID:
21562753
38.

Prostate biopsies from black men express higher levels of aggressive disease biomarkers than prostate biopsies from white men.

Kim HS, Moreira DM, Jayachandran J, Gerber L, Bañez LL, Vollmer RT, Lark AL, Donovan MJ, Powell D, Khan FM, Freedland SJ.

Prostate Cancer Prostatic Dis. 2011 Sep;14(3):262-5. doi: 10.1038/pcan.2011.18. Epub 2011 Apr 26.

PMID:
21519348
39.

Editorial comment. Body mass index adjusted prostate-specific antigen and its application for prostate cancer screening.

Bañez LL.

Urology. 2010 Nov;76(5):e4. doi: 10.1016/j.urology.2010.05.035. No abstract available.

PMID:
21056250
40.

Factors affecting patient radiation exposure during percutaneous nephrolithotomy.

Mancini JG, Raymundo EM, Lipkin M, Zilberman D, Yong D, Bañez LL, Miller MJ, Preminger GM, Ferrandino MN.

J Urol. 2010 Dec;184(6):2373-7. doi: 10.1016/j.juro.2010.08.033. Epub 2010 Oct 16.

PMID:
20952034
41.

Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database.

Hamilton RJ, Banez LL, Aronson WJ, Terris MK, Platz EA, Kane CJ, Presti JC Jr, Amling CL, Freedland SJ.

Cancer. 2010 Jul 15;116(14):3389-98. doi: 10.1002/cncr.25308.

42.

Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer.

Bañez LL, Sun L, van Leenders GJ, Wheeler TM, Bangma CH, Freedland SJ, Ittmann MM, Lark AL, Madden JF, Hartman A, Weiss G, Castaños-Vélez E.

J Urol. 2010 Jul;184(1):149-56. doi: 10.1016/j.juro.2010.03.012. Epub 2010 May 15.

PMID:
20478579
43.

Editorial comment to Serum prostate-specific antigen is better correlated to body surface area than body mass index in a population of healthy Korean men.

Bañez LL.

Int J Urol. 2010 Jun;17(6):583-4. doi: 10.1111/j.1442-2042.2010.02532.x. Epub 2010 Apr 23. No abstract available.

44.

Defining and treating high-risk prostate cancer: can we do better?

Gerber L, Bañez LL, Freedland SJ.

Eur Urol. 2010 Jul;58(1):8-9. doi: 10.1016/j.eururo.2010.03.030. Epub 2010 Mar 26. No abstract available.

PMID:
20363552
45.

Editorial comment.

Moreira DM, Bañez LL, Freedland SJ.

J Urol. 2010 May;183(5):1796. doi: 10.1016/j.juro.2010.01.099. Epub 2010 Mar 17. No abstract available.

PMID:
20299054
46.

Editorial comment.

Bañez LL, Freedland SJ.

Urology. 2010 Mar;75(3):652-3; author reply 653. doi: 10.1016/j.urology.2009.07.1278. No abstract available.

PMID:
20211373
47.

The influence of hepatic function on prostate cancer outcomes after radical prostatectomy.

Bañez LL, Loftis RM, Freedland SJ, Presti JC Jr, Aronson WJ, Amling CL, Kane CJ, Terris MK.

Prostate Cancer Prostatic Dis. 2010 Jun;13(2):173-7. doi: 10.1038/pcan.2010.3. Epub 2010 Mar 2.

48.

Editorial comment.

Bañez LL.

J Urol. 2010 Apr;183(4):1353-4; discussion 1354. doi: 10.1016/j.juro.2009.12.114. Epub 2010 Feb 19. No abstract available.

PMID:
20171684
49.

Association between statins and prostate tumor inflammatory infiltrate in men undergoing radical prostatectomy.

Bañez LL, Klink JC, Jayachandran J, Lark AL, Gerber L, Hamilton RJ, Masko EM, Vollmer RT, Freedland SJ.

Cancer Epidemiol Biomarkers Prev. 2010 Mar;19(3):722-8. doi: 10.1158/1055-9965.EPI-09-1074. Epub 2010 Feb 16.

50.

Words of wisdom. Re: Effects of simvastatin, acetylsalicylic acid, and rosiglitazone on proliferation of normal and cancerous prostate epithelial cells at therapeutic concentrations.

Masko EM, Bañez LL, Freedland SJ.

Eur Urol. 2010 Mar;57(3):542-3. No abstract available. Erratum in: Eur Urol. 2010 Jul;58(1):e15. Bañez, Masko [corrected to Bañez, Lionel L].

PMID:
20135759

Supplemental Content

Loading ...
Support Center